
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CORRECTION article
Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1417603
This article is a correction to:
Astragalus–Scorpion Drug Pair Inhibits the Development of Prostate Cancer by Regulating GDPD4-2/PI3K/AKT/mTOR Pathway and Autophagy
The final, formatted version of the article will be published soon.
You have multiple emails registered with Frontiers:
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Corrigendum on: You X, Wu Y, Li Q, Sheng W, Zhou Q and Fu W (2022) Astragalus-Scorpion Drug Pair Inhibits the Development of Prostate Cancer by Regulating GDPD4-2/PI3K/AKT/mTOR Pathway and Autophagy. Front. Pharmacol. 13:895696. doi: 10.3389/fphar.2022.895696 In the published article, there was an error in the legend for Figure 4 as published. The original description has ambiguity, which may cause readers to misunderstand. The corrected legend appears below. In the published article, there was an error in the legend for Figure 5 as published. The original description was not in consistent with the its results. The corrected legend appears below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.In the published article, there was an error in Figure 3 as published. We mistakenly pasted the WB blot image of p-PI3K at the place of p-AKT and PI3K. The corrected Figure 3 and its caption appear below. PAGE \* Arabic \* MERGEFORMAT 3
Keywords: Astragalus-scorpio, prostate cancer, PI3K/AKT, Astragaloside IV, Polypeptide extract from scorpion venom, Autophagy
Received: 15 Apr 2024; Accepted: 05 Mar 2025.
Copyright: © 2025 You, Wu, Li, Sheng, Zhou and Fu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Qing Zhou, Department of Andrology, The First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha, Anhui Province, China
Wei Fu, Department of Andrology, Shenzhen Baoan District Hospital of Traditional Chinese Medicine, Shenzhen, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.